|
Volumn 2, Issue 6, 2001, Pages 752-754
|
RU-79115 Aventis Pharma
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
EPEREZOLID;
GYRASE INHIBITOR;
LINEZOLID;
RU 79115;
UNCLASSIFIED DRUG;
VANCOMYCIN;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIBACTERIAL ACTIVITY;
BACTERIAL INFECTION;
DRUG BIOAVAILABILITY;
DRUG METABOLISM;
DRUG SYNTHESIS;
ENTEROCOCCUS;
ENTEROCOCCUS FAECIUM;
GRAM NEGATIVE INFECTION;
IN VITRO STUDY;
IN VIVO STUDY;
MINIMUM INHIBITORY CONCENTRATION;
MOUSE;
NONHUMAN;
SEPTICEMIA;
SHORT SURVEY;
STAPHYLOCOCCUS;
STAPHYLOCOCCUS AUREUS;
STRUCTURE ACTIVITY RELATION;
TOXICITY TESTING;
ANIMALS;
ANTI-BACTERIAL AGENTS;
COUMARINS;
DNA TOPOISOMERASES, TYPE II;
ENTEROCOCCUS;
ENZYME INHIBITORS;
GRAM-POSITIVE BACTERIA;
HEXOSES;
MICE;
PATENTS;
STAPHYLOCOCCUS;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 0034784587
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
Times cited : (5)
|
References (8)
|